ReviewCancer medicine2026
Racial and Socioeconomic Healthcare Disparities in Access to Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Blood Cancers.
Review in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Health equity in rheumatology-the uneven landscape of cellular therapy.Clinical rheumatology · 2026Article
- BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.Advances in therapy · 2026Article
- Racial and Socioeconomic Healthcare Disparities in Access to Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Blood Cancers.Cancer medicine · 2026Review
- Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth disparities remain a critical global public health challenge, particularly in access to advanced treatments for blood cancers. Racial and socioeconomic factors influence healthcare accessibility, contributing to inequities in patient outcomes. Despite the potential of CAR-T therapy in treating blood cancers, disparities in financial resources, education, gender, and race hinder equitable access. This study evaluates literature on CAR-T therapy to identify access disparities and proposes policy recommendations.
methodsThe PRISMA-ScR guidelines were followed for study selection and reporting. A comprehensive search strategy was used across databases like PubMed and Google Scholar, using keywords and MeSH terms. Inclusion criteria included peer-reviewed studies in English since 2000. A basic quality appraisal was conducted to ensure the relevance and credibility of included studies, despite the diversity of study designs and the primary focus on mapping key themes across the literature.
resultsTwenty-five relevant (25) studies, including analytical studies, observational studies, and literature reviews, were analyzed. Findings indicate significant racial and socioeconomic disparities in CAR-T therapy accessibility, with financial constraints, lack of awareness, and systemic biases limiting equitable distribution. Challenges include high treatment costs, lack of insurance coverage, and underrepresentation of minority groups in trials.
conclusionAddressing these disparities requires targeted policy interventions, increased funding, and improved patient education. Continued research and collaboration are essential to ensure equitable access for all individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.